Our mission is to develop novel, innovative and targeted medicines that augment endogenous anti-tumour immunity to further improve outcomes for patients affected by cancer. When harnessed appropriately, the immune system is an extremely potent and specific endogenous anti-tumour mechanism. Our first-in-class agonist antibody has been designed to address current clinical challenges associated with immunotherapy such as improving the rate and quality of responses, while also addressing the clinical challenges that have been encountered with recombinant IL-21.